Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses results of the CheckMate 743 trial, which suggests nivolumab plus ipilimumab should be considered the new standard of care in first-line treatment of unresectable malignant pleural mesothelioma, regardless of the histology subtype (Abstract 3).
Marina C. Garassino, MD, of the Istituto Nazionale dei Tumori di Milano, discusses the global registry she and her colleagues created to track and address the 35% higher mortality risk from COVID-19 among patients with lung cancer who are treated with chemotherapy.
Misako Nagasaka, MD, of the Barbara Ann Karmanos Cancer Institute, discusses results of the ORIENT-11 trial, which showed that, although sintilimab plus pemetrexed and platinum significantly improved progression-free survival, the combination only nominally improved overall survival in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (Abstract 1).
Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation ALK inhibitor, is superior to crizotinib in terms of progression-free survival as well as efficacy in central nervous system metastases for patients with ALK-positive non–small cell lung cancer (Abstract 2).
